Nasdaq5d
COSCIENS Biopharma Initiates Phase 2a Clinical Efficacy Study for Avenanthramides Product Following Successful Phase 1 Safety Results
COSCIENS Biopharma Inc. has announced the initiation of its Phase 2a clinical efficacy study for its avenanthramides product, which aims to manage inflammation-related conditions. Following a ...
Incyte announces STOP-HS1, STOP-HS2 studies met primary endpoint
Incyte (INCY) announced topline results from its Phase 3 STOP-HS clinical trial program evaluating the safety and efficacy of povorcitinib, an ...
Yahoo Finance6d
Rivus Pharmaceuticals Announces Publication of Phase 2a HuMAIN Trial of HU6 in Patients with Obesity-Related Heart Failure in JAMA Cardiology
oral therapy in Phase 2 clinical development, is a Controlled Metabolic Accelerator, a new class of investigational therapies designed to selectively reduce body fat while maintaining muscle mass ...
Morningstar6d
Rivus Pharmaceuticals Announces Publication of Phase 2a HuMAIN Trial of HU6 in Patients with Obesity-Related Heart Failure in JAMA Cardiology
placebo (-0.19 L) in patients whose body composition was assessed by MRI. Although this Phase 2a study was a short duration of 19 weeks, additional secondary endpoints were assessed to evaluate ...
Investing5d
COSCIENS advances to Phase 2a study for inflammation treatment
TORONTO - COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI), a developer of health and wellness products currently trading at $2.69, has announced the initiation of the Phase 2a clinical efficacy ...
Investing5d
COSCIENS advances to Phase 2a study for inflammation treatment
TORONTO - COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI), a developer of health and wellness products currently trading at $2.69, has announced the initiation of the Phase 2a clinical efficacy ...